Assertio Sells Nucynta® Franchise to Collegium for US$375 M
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 2 (Table of Contents)
Published: 14 Feb-2020
DOI: 10.3833/pdr.v2020.i2.2512 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Shedding the last of its scandal-plagued opioid business, Assertio has agreed to sell its Nucynta® (tapentadol) franchise to Collegium Pharmaceutical in exchange for US$375 M in cash...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS